IMPACT OF HEMATOLOGICAL PARAMETER TRENDS ON ATHLETE RECOVERY FOLLOWING TREATMENT OF SEVERE APLASTIC ANEMIA WITH ELTROMBOPAG AND IMMUNOSUPPRESSANTS

Abstract

Objective: To examine the impact of enhanced medical treatment combining eltrombopag with immunosuppressants on hematological parameters in athletes suffering from severe aplastic anemia (SAA), an underrecognized condition in sports medicine. Methods: This study retrospectively analyzed 100 athletes diagnosed with SAA who were treated from January 2018 to June 2022. The athletes were allocated into two groups: the control group (50 athletes) received standard androgen therapy along with immunosuppressants, while the study group (50 athletes) received an additional treatment with eltrombopag. We compared the clinical effectiveness, hematological parameters, symptom scores, serum inflammatory markers, sleep quality indices, and overall quality of life between the two groups. Results: The study group, treated with the addition of eltrombopag, demonstrated a significant improvement in clinical efficacy (96%) compared to the control group (82%). Enhancements were noted in hemoglobin levels, reticulocyte counts, and platelet counts. Symptoms such as fatigue, dizziness, and appetite loss were significantly alleviated in the study group. Furthermore, inflammatory markers such as serum CRP, PCT, and TNF-alpha showed greater reductions. Sleep quality and overall life quality scores were also notably better in the study group. Conclusion: For athletes with SAA, the integrated approach of androgen therapy, immunosuppression, and eltrombopag not only enhances hematological outcomes but also reduces symptoms and inflammation, thereby improving sleep quality and life quality. This strategy could be particularly beneficial in sports medicine, providing a comprehensive treatment modality that supports both recovery and performance sustainability.